Brainstorm Cell Therapeutics Inc. (BCLI) Financials

BCLI Assets vs Liabilities
DateAssetsLiabilities
June 30, 2026 472000 12.4 million
March 31, 2026 571000 11.8 million
Dec. 31, 2025 715000 11.0 million
Sept. 30, 2025 1.4 million 9.1 million

BCLI Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 -895000 2.2 million
March 31, 2026 -1.3 million 133000
Dec. 31, 2025 -740000 143000
Sept. 30, 2025 -1.1 million 157000

BCLI Net Income

No data available :(

BCLI Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 22000 - -
March 31, 2026 15000 - 159000
Dec. 31, 2025 29000 208000 208000
Sept. 30, 2025 5000 - 326000

BCLI Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 11.0 million
March 31, 2026 11.0 million
Dec. 31, 2025 9.3 million
Sept. 30, 2025 11.0 million

BCLI Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 - 917000 2.7 million -
March 31, 2026 - 725000 1.3 million -
Dec. 31, 2025 - -3.3 million -4.4 million -
Sept. 30, 2025 - 899000 1.1 million -

BCLI Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 - 46000
March 31, 2026 178000 37000
Dec. 31, 2025 703000 48000
Sept. 30, 2025 - -

BCLI

Price: $0.87

52 week price:
0.46
1.69

Earnings Per Share: -0.88 USD

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 566900

Ebitda: -2.4 million

Market Capitalization: 10.3 million

Links: